Login to Your Account



Altus Shares Take Beating over CF Study Result Questions

By Donna Young


Wednesday, August 13, 2008
Although top-line results of a Phase III efficacy trial showed that Altus Pharmaceuticals Inc.'s cystic fibrosis drug Trizytek (ALTU-135) hit its primary endpoint of improvement in fat absorption, the benefit was smaller than expected and results differed across various geographies. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription